Objective-Little is known about the role(s) B cells play in obesity-induced metabolic dysfunction. This study used a mouse with B-cell-specific deletion of Id3 (Id3 Bcell KO ) to identify B-cell functions involved in the metabolic consequences of obesity. Approach and Results-Diet-induced obese Id3 Bcell KO mice demonstrated attenuated inflammation and insulin resistance in visceral adipose tissue (VAT), and improved systemic glucose tolerance. VAT in Id3 Bcell KO mice had increased B-1b B cells and elevated IgM natural antibodies to oxidation-specific epitopes. B-1b B cells reduced cytokine production in VAT M1 macrophages, and adoptively transferred B-1b B cells trafficked to VAT and produced natural antibodies for the duration of 13-week studies. B-1b B cells null for Id3 demonstrated increased proliferation, established larger populations in Rag1 −/− VAT, and attenuated diet-induced glucose intolerance and VAT insulin resistance in Rag1 −/− hosts. However, transfer of B-1b B cells unable to secrete IgM had no effect on glucose tolerance. In an obese human population, results provided the first evidence that B-1 cells are enriched in human VAT and IgM antibodies to oxidation-specific epitopes inversely correlated with inflammation and insulin resistance. Conclusions-NAb-producing B-1b B cells are increased in Id3 Bcell KO mice and attenuate adipose tissue inflammation and glucose intolerance in diet-induced obese mice. Additional findings are the first to identify VAT as a reservoir for human B-1 cells and to link anti-inflammatory IgM antibodies with reduced inflammation and improved metabolic phenotype in obese humans. (Arterioscler Thromb Vasc Biol. 2016;36:682-691.
O besity is an epidemic in the Western world, and dramatically increasing rates in developing countries have made it one of the prominent global health concerns of the 21st century. Obesity-induced visceral adipose tissue (VAT) inflammation leads to systemic insulin resistance and glucose intolerance. 1 Although macrophages and T cells have been implicated in this process, 2,3 emerging evidence suggests that B cells also modulate obesity-induced adipose tissue inflammation and insulin resistance.
B cells have been identified in murine and human adipose tissue, [4] [5] [6] [7] [8] and localize to sites of inflammation. 9 Recently, IgG from diet-induced obese (DIO) mice was shown to drive adipose tissue inflammation and promote systemic insulin resistance. 4 These pathogenic IgG antibodies were localized in VAT and came from adaptive B-2 B cells-the major B cell subset that differentiate into memory B and plasma cells capable of producing class-switched, high affinity antibodies. 10 Importantly, IgM antibodies did not impair metabolic function in the same mice, suggesting an isotype-dependent effect.
B-1 B cells, a self-renewing innate B-cell population that differ from B-2 cells in response to stimuli and antibody repertoire, 11 produce a major portion of plasma IgM in uninfected mice. 12 B-1 B cells are further divided into B-1a and B-1b subsets that have overlapping functions, but exhibit differences in activation and response to infection. [13] [14] [15] [16] Both subsets produce evolutionarily conserved IgM antibodies, which are termed natural antibodies (NAbs) because they contain few nontemplated additions (N additions), few mutations, and often recognize epitopes expressed on both invading pathogens and dying or damaged self-cells. 17, 18 In contrast to IgG, B-1-derived IgM NAbs have direct and indirect anti-inflammatory functions 19, 20 and are thought to protect in specific instances of diet-induced chronic inflammation. 20, 21 As B-1 B cells are enriched in omental adipose tissue, 5 they may be important regulators of VAT function. Despite this, the roles for B-1 B cells and their IgM NAbs in mediating obesity-induced adipose tissue inflammation and insulin resistance are poorly understood.
Although IgM NAbs similar to those derived from murine B-1 B cells are well documented in humans, 22, 23 identifying a human B-1 B cell has been elusive. Recently however, a subset of circulating B cells in humans was shown to share several functional properties unique to murine B-1 B cells. 24 However, these cells have yet to be identified outside of the circulation and it is unknown whether, such as murine B-1 cells, these B cells are enriched in adipose tissue.
Id3 is a ubiquitously expressed dominant-negative transcription regulator that, along with its binding partners, mediates various stages of B-cell development and function. 25, 26 Mice globally null for Id3 have impaired antigen-specific antibody responses 25 and altered levels of circulating IgM. 27, 28 Recent work from our group has shown a role for Id3 in B-cell regulation of diet-induced chronic inflammation. 28, 29 Additional studies using a mouse model of obesity showed that mice with global deletion of Id3 are protected against diet-induced VAT expansion. 30 Together, these findings suggest Id3 may be a key factor that links B-cell function and obesity. Previous studies of the role of Id3 in atherosclerosis have identified cell type-specific mechanisms whereby Id3 regulates disease pathology, 31, 32 underscoring the importance of using B-cell-specific deletion of Id3 to define mechanisms of B-cell regulation in DIO.
In this report, we use mice null for Id3 specifically in B cells (Id3 Bcell KO ) to test whether B-1 B cells and IgM NAbs mediate the inflammatory and metabolic effects of DIO. We expand on our murine results with analysis of IgM NAbs and adipose tissue B cells in patients undergoing bariatric surgery. Together, results demonstrate that B-1b B cells attenuate the metabolic effects of DIO in an IgM-dependent manner. Furthermore, we identify B-1 B cells in human VAT and provide evidence that specific IgM NAbs negatively associate with insulin resistance in an obese human population.
Materials and Methods
Expanded materials and methods can be found in the online-only Data Supplement.
Results

B-Cell-Specific Deletion of Id3 Attenuates Glucose Intolerance and VAT Insulin Resistance in DIO mice
To evaluate whether Id3 expression is important for B-cellmediated effects on DIO, Id3 Bcell KO , 31, 32 and wild-type (WT) littermates were fed either chow or high-fat diet (HFD) for 12 weeks. As expected, there was a marked increase in body and visceral depot weights in the HFD fed group compared with chow, yet there were no genotype-dependent differences in epididymal adipose tissue mass or body weight ( Figure 1A) . Although B-cell-specific loss of Id3 did not completely correct the glucose intolerance because of DIO, Id3 Bcell KO mice had significantly improved glucose clearance compared with littermate controls ( Figure 1B ). There were no genotype-dependent differences in systemic insulin resistance or serum free fatty acid levels ( Figure IA in the online-only Data Supplement). However, insulin sensitivity as measured by insulin-stimulated AKT phosphorylation was elevated in omental adipose tissue ( Figure 1C ). No differences were observed in skeletal muscle or liver ( Figure IB in the onlineonly Data Supplement). Taken together, results suggest that B cells may contribute to tissue-specific effects that may improve metabolic function associated with DIO in an Id3dependent manner.
To test whether the attenuated glucose intolerance in the DIO mice stemmed from loss of Id3 in a B-2 cell, either 10 7 splenic B-2 cells from HFD-primed 4 WT or Id3 −/− donors, or vehicle control, were injected intraperitoneally into DIO μMT hosts. Because μMT mice contain a deletion in the μ heavy chain required for surface B-cell receptor expression and essential for both B-1 and B-2 development, these mice lack mature B cells. 33 Recipient mice were continued on an HFD and tested for glucose tolerance at 2 and 6 weeks post transfer ( Figure 1D ). No differences in body weight, fat mass ( Figure  1E ), or B-cell engraftment ( Figure IC in the online-only Data Supplement) were observed. Although all the 3 groups demonstrated similar glucose tolerance at week 2 ( Figure 1F ), mice receiving WT B-2 cells had significantly impaired glucose clearance compared with vehicle controls 6 weeks post transfer ( Figure 1F ). This corroborates previous findings 4 that B-2 cells impair glucose homeostasis. However, hosts receiving WT and Id3 −/− B-2 cells had nearly identical glucose clearance, providing evidence that improved glucose tolerance in Id3 Bcell KO mice is not because of loss of Id3 function in a B-2 B cell, and suggesting that other B-cell subsets may also modulate HFD-induced glucose intolerance.
DIO Id3 Bcell KO Mice Have Increased B-1b B Cells, Total IgM, and T15-IgM Antibodies in Adipose Tissue
Immune cells within adipose tissue can affect glucose homeostasis in a subset-dependent manner. 2, 3 Flow cytometry studies in epididymal fat from DIO Id3 Bcell KO mice revealed no differences in F4/80 + CD206 − CD11c + M1 or F4/80 + CD206 + CD11c − M2 macrophages 34 or total CD3ε + T cells (Figure 2A ). There was a trend toward an increase in B-2 cells, although this change did not reach statistical significance. In contrast, Id3 Bcell fat compared with WT littermates (Figure 2A ). Further analysis revealed a specific increase in epididymal B-1b, but not B-1a, B cells in DIO Id3 B cell KO mice ( Figure 2B ). Among the many known IgM antibodies produced by B-1 B cells, the best studied are members of the T15 NAb family that bind phosphorylcholine (PC), 35 an epitope present on pneumococcal cell membranes as well as on phospholipids of oxidized low-density lipoprotein (LDL) and apoptotic cells. 36 These antibodies (T15-IgM or PC-IgM) have anti-inflammatory capacities, 19, 20 suggesting they may have important regulatory functions within VAT. Epididymal adipose tissue IgM ( Figure 2C ) and T15-IgM ( Figure 2D ) levels were elevated in DIO Id3 Bcell KO mice compared with WT. In addition, circulating malondialdehyde (MDA)-LDL IgM and LDL-IgM immune complexes (IC), both associated with reduced inflammation and reduced risk of myocardial infarction in a human population, 37, 38 were also elevated or showed a trending increase in Id3 B cell KO mice ( Figure 2E ). We observed no variations in circulating or adipose tissue IgG antibodies, including B-2-derived pathogenic IgG2b and IgG2c isotypes ( Table I in Omental fat refers to the fatty band attached to the greater curvature of the stomach. 39 Murine and human omental adipose tissue is similar in structure 40 and contains B-cell-rich clusters of immune cells termed milky spots. Enriched B-cell numbers help distinguish milky spots from fat-associated lymphoid clusters found in the mesentery that contain high numbers of natural helper cells, but few B cells. 41 Consistent with previous reports, 5 substantially more B-1 B cells were found in omental fat than epididymal fat relative to tissue mass ( Figure  3A and 3B), and only omental adipose tissue contained milky spot clusters that stained heavily for the B-cell marker B220 ( Figure 3C ). In addition, omental fat cultured ex vivo from Id3 Bcell KO mice produced 3-fold more T15-IgM than controls ( Figure 3D ), providing evidence that PC-specific IgM is produced in omental adipose tissue in proportion to the number of B-1b cells. Together, our findings indicate that Id3 is an important regulator of adipose tissue B-1b B-cell population size, and that loss of Id3 leads to significantly more B-1b B cells, and subsequently elevated local T15-IgM NAb production. Population maintenance depends on a balance between cell proliferation and cell death, and increased cell numbers can result from defective regulation of either process. To test whether Id3 mediates proliferation or apoptosis in B-1b B cells independent of adoptive transfer, WT and Id3 Bcell KO mice were treated with lipopolysaccharide-a rapid B-1b activator. 43 Mice were then injected with BrdU to label proliferating cells, and B-1b B cells in omental fat were analyzed for proliferation and apoptosis. Lipopolysaccharide-activated B-1b B cells in omental adipose tissue displayed no Id3-dependent differences in BrdU incorporation ( Figure 4B ). However, loss of Id3 in B cells led to lower Annexin V staining ( Figure 4B 
Loss of Id3 in B Cells Leads to Increased T15-IgM Production in Omental Adipose Tissue
Loss of Id3 Promotes Omental B-1b B-Cell Survival
Loss of Id3 in B Cells Attenuates HFD-Induced Inflammation in Omental Adipose Tissue
Omental fat of Id3 Bcell KO mice contains higher numbers of B-1b B cells and produces more anti-inflammatory T15-IgM NAbs. To determine if loss of Id3 in B cells attenuates HFD-induced adipose tissue inflammation, inflammatory cytokine secretion by omental adipose tissue was evaluated in DIO WT and Id3 Bcell KO mice. Indeed, although no differences were observed between chow-fed animals (data not shown), omental fat from DIO Id3 Bcell KO mice produced significantly less TNFα and interferon-γ compared with diet-matched WT controls ( Figure 5A ). Although recent studies have identified IL-10 as a mechanism by which B-1 B cells limit inflammation, we did not observe differential IL-10 secretion in adipose tissue of Id3 B cell KO DIO mice ( Figure IV in the online-only Data Supplement).
DIO is characterized by infiltrating adipose tissue M1 macrophages that produce inflammatory cytokines, such as TNFα and monocyte chemoattractant protein-1 (MCP-1). Therefore, we hypothesized that despite no difference in macrophage number (Figure 2A ), proinflammatory cytokine production may be reduced in omental M1 macrophages of Id3 B cell KO DIO mice. Indeed, M1 macrophages from omental adipose tissue of Id3 B cell KO DIO mice lacked the DIO-induced TNFα and MCP-1 expression present in WT M1 macrophages ( Figure 5B ). We next sought to determine whether secreted B-1b B-cell products can attenuate adipose tissue macrophage production of these cytokines. Omental depots from WT DIO mice were treated with conditioned media from control and activated B-1b B cells, and flow cytometry was used to measure lipopolysaccharide-induced TNFα and MCP-1 production in adipose tissue macrophages. Results demonstrated that secreted factors from activated B-1b B cells blunted TNFα and MCP-1 production in M1, but not M2, macrophages ( Figure 5C ). Together, these findings provide evidence that B-1b B cells can play a regulatory role in reducing adipose tissue inflammation.
B-1b B Cells Lacking Id3, But Not the Ability to Secrete IgM, Attenuate Diet-Induced Glucose Intolerance
Findings in the Id3 Bcell KO mouse suggest that improved B-1b B-cell survival leads to increased B-1b B-cell number and elevated local IgM production that may protect against downstream metabolic dysfunction. To test this, FACSsorted B-1b B cells from WT, Id3 Bcell KO , or sIgM −/− donors were adoptively transferred into Rag1 −/− hosts that were then placed on an HFD for 12 weeks ( Figure 6A ). Although B cells from sIgM −/− mice express surface IgM and secrete IgG, they cannot secrete IgM. 44 Total plasma IgM, LDL IgM-IC, and MDA-LDL IgM levels were tested at 2 and 12 weeks after diet initiation ( Figure V in the online-only Data Supplement). Antibody levels increased with time, Figure 6B ), hosts that received Id3 Bcell KO B-1b B cells had improved glucose tolerance compared with vehicle controls, and WT hosts showed a trend toward improved glucose clearance ( Figure 6C ). No differences were seen between hosts that received B-1b B cells from sIgM −/− and vehicle controls ( Figure 6C ). Additional analysis indicated significantly improved insulin signaling in omental adipose tissue from hosts that received B-1b B cells from Id3 B cell KO donors compared with vehicle controls ( Figure 6D) . These results suggest a role for B-1b B cells in attenuating the metabolic consequences of obesity that is enhanced in the absence of Id3 and is dependent on the ability of the B-1b B cell to secrete IgM NAbs.
PC-IgM NAbs in Circulation and Within Omental Adipose Tissue of Humans Negatively Correlate With MCP-1
PC-recognizing IgM NAbs derived from B-1 B cells have anti-inflammatory characteristics. 19, 20 To determine if PC-IgM was associated with a serum marker of inflammation, we measured circulating levels of MCP-1 in a cohort of bariatric surgery patients (cohort 1; 122 patients enrolled between May 2009 and August 2010). The baseline clinical characteristics of this cohort are shown in Table II in the online-only Data Supplement. Circulating MCP-1-a macrophage chemoattractant protein known to be highly predictive of insulin resistance 45 -inversely associated with PC-IgM in both the circulation and within the omental adipose tissue ( Table  III in the online-only Data Supplement). Our studies provide evidence that PC-IgM NAbs are present in human omental adipose tissue and are associated with reduced MCP-1.
IgM NAbs and ApoB-IC Correlate With High-Density Lipoprotein Levels and Improved LP-IR Scores
Several studies have revealed that in addition to PC-IgM, IgM NAbs directed at other oxidation-specific epitopes (OSE) associate with reduced inflammation and decreased risk of death, myocardial infarction, and stroke in prospectively followed subjects from the general community 37, 38 To determine if other IgM NAbs were associated with metabolic dysfunction, we scored each patient in cohort 1 from 0 (most insulin sensitive) to 100 (most insulin resistant) using a nuclear magnetic resonance-based lipoprotein insulin resistance (LP-IR) panel. Because nuclear magnetic resonance has the capacity to measure both lipoprotein size and particle concentration, LP-IR accounts for parameters missed by normal lipid panels, and it is highly predictive of progressive insulin resistance after multivariate analysis. 46, 47 In contrast to methods used for measuring β-cell function such as HOMA-IR, LP-IR measurements are not affected by acute changes in glucose or insulin. Thus, LP-IR is reflective of long-term metabolic function and better reflects overall metabolic health. Although there was no correlation with LP-IR scores and circulating PC-IgM in this population (data not shown), LP-IR had a significant negative association with IgM apoB IC (IgM-IC) and a trending inverse correlation with IgM antibodies to MDA-LDL (Table) . Both IgM-IC and IgM MDA-LDL were positively associated with high-density lipoprotein. In contrast to IgM, no associations were observed with IgG-IC or IgG MDA-LDL. Together, our results provide evidence that IgM NAbs directed at OSE may be associated with protective phenotypes in an obese human population, suggesting a role for B-1 B cells in regulating metabolic syndrome in humans.
Human Omental Adipose Tissue Contains B-1-Like Cells and PC-IgM
Recently, Griffin et al 24 identified a subset of circulating B cells (CD20 + CD27 + CD43 + ) in humans that share several unique properties of murine B-1 B cells. To determine if this subset of B-1 B cells are found in human omentum, we performed flow cytometry on sections of omental fat harvested from a second smaller group of patients undergoing bariatric surgery (cohort 2; 16 patients enrolled between October 2012 and October 2013). Interestingly, a marked enrichment of B-1 cells was found in omental fat compared with subcutaneous fat or blood in 4 of 16 patients analyzed. Figure 7A is a representative flow cytometry plot of the patients whose samples displayed marked enrichment. B-1 cells in omental adipose tissue directly correlated with plasma PC-binding IgM levels ( Figure 7B ). Together, these findings show for the first time that B-1 B cells are enriched in human omental adipose tissue and the percentage of B-1 cells directly correlates with circulating IgM to PC. 
Discussion
Recent studies have demonstrated subset-specific roles for B cells in both aggravating and regulating the perturbations associated with obesity. Winer et al 4 demonstrated that B-2 B cells promote insulin resistance and glucose intolerance through production of pathogenic antibodies. Additional studies have shown that sorted splenic B-2 B cells from obese mice secrete more IL-6 and MIP-2 and less IL-10 compared with lean controls, 48 and circulating B cells (of which the vast majority are B-2) from patients with type 2 diabetes mellitus are also skewed toward a proinflammatory phenotype after toll-like receptor stimulation. 49 Our adoptive transfers of B-2 B cells provide further evidence that B-2 B cells promote metabolic dysfunction during DIO. In contrast, B-1a B cells were recently shown to protect against the inflammatory and metabolic consequences of DIO through a combination of IgM and IL-10 production, 50 and B-cell-derived IL-10 reduces adipose tissue inflammation and insulin resistance caused by DIO. 51, 52 Our findings add to these studies and indicate for the first time a role for B-1b-derived IgM NAbs in attenuating adipose tissue inflammation and metabolic dysfunction in obesity. Although CD5 − B-1b and CD5 + B-1a B cells are sister populations, they have distinct developmental origins 53 and functional properties. 16 Although it has long been recognized that B-1a B cells spontaneously produce IgM NAbs against OSE generated during inflammation and cell death, such as E06/T15 against PC and NA17/E014 against MDA, 22 the role of B-1b B cells in producing these important antibodies and their impact in DIO is poorly understood. We found Id3 B cell KO mice to display an elevated B-1b population at baseline that persisted during obesity progression. Interestingly, we only observed inflammatory and metabolic differences after DIO. It is possible that B-1b B cells function to limit inflammatory processes that become exaggerated in obesity. This explanation fits with our findings that B-1b B cells specifically attenuated M1 macrophage inflammation, as M1 macrophages are rare in lean adipose tissue.
In addition to attenuated obesity-induced inflammation, Id3 B cell KO mice showed improved insulin-stimulated pAKT signaling specifically in omental fat, but not in skeletal muscle or liver. Because skeletal muscle is the main tissue that accounts for insulin-stimulated glucose disposal, 54 Id3mediated B cell effects on insulin signaling in adipose alone may not be sufficient to result in systemic effects. Indeed, we did not observe differences in systemic insulin resistance as measured by ITT in Id3 B cell KO mice.
B-1-derived IgM NAbs can reduce inflammation and promote apoptotic cell clearance 17, 22, 55 ; processes that become dysregulated during the progression of obesity. 39, 56 However, it is currently unclear whether specific IgM antibodies play important roles in mediating the effects of obesity. The well-studied T15 family of PC-IgM NAbs have known antiinflammatory properties 19 and are thought to prevent macrophage lipid uptake and apoptotic cell accumulation in models of atherosclerosis. 21, 57 However, Shen et al 50 reported no metabolic effect when PC-IgM was infused into DIO μMT mice. Interestingly, a partial loss of B-1a B-cell attenuation of glucose intolerance was observed when the B-1a B cells could not secrete IgM. 50 Although these seemingly disparate findings could be explained by insufficient amount or localization of the infused antibody, it is likely that other IgM antibodies are needed for the full effect on glucose handling. Notably, our results in mice and humans support this hypothesis as we demonstrated complete loss of the protective effect provided by B-1b B cells when they were unable to secrete IgM. No associations with PC-IgM and insulin sensitivity were found in obese humans, but trending and significant associations between insulin sensitivity and IgM antibodies and IC to other OSE were identified. It is of interest that it has recently been shown that IgM to both MDA-LDL and oxidized low-density lipoprotein epitopes display a remarkably high heritability, in the range of h(2), 0.6 to 0.8, suggesting that there may be a strong genetic component to these anti-inflammatory innate responses, which may have confounded these association studies. 58 Together, these results suggest that certain IgM clones may play differing roles in mediating inflammation and metabolic dysfunction in obesity. Identifying these associations is an important first step toward understanding the role IgM antibodies play in obesity-associated metabolic disease.
Much of the knowledge about immune regulation of disease has come from murine studies, and in many cases, the relevance to humans remains to be deciphered. Although immunohistochemical analysis has demonstrated B cells within human omental fat, 7,8 the lack of a known human B-1 cell equivalent, along with the multiple markers needed to identify subsets and the challenges of performing flow cytometry on human omental adipose tissue had made subset analysis difficult. Recently, a circulating human CD20 + CD27 + CD43 + B cell with several characteristics similar to murine B-1 B cells was identified. 24 Here, we demonstrate for the first time using multicolor flow cytometry of human omental fat, that like murine B-1 B cells, CD20 + CD27 + CD43 + B cells are not only present in omental fat but also in some patients were markedly enriched compared with subcutaneous adipose tissue and blood. Not all omental adipose tissue samples demonstrated this marked enrichment, possibly because of uneven clustering and distribution of milky spots within individual depots, variable sampling at the time of surgery, or because of differences in individual patients, such as the genetic regulation of B-1 cell NAb production implied by the heritability of IgM to OSE noted above. Nonetheless, the percentage of omental B cells that were CD20 + CD27 + CD43 + B cells correlated with circulating PC-IgM levels. Our findings add to the known similarities between murine B-1 B cells and human CD20 + CD27 + CD43 + B cells, and indicate that further analysis of omental adipose tissue may improve our understanding of the role B-1 B cells play in metabolic regulation.
In summary, this study provides the first evidence that B-1b B cells and the anti-inflammatory IgM NAbs they produce attenuate diet-induced glucose intolerance in mice. Moreover, our findings are the first to identify CD20 + CD27 + CD43 + B cells and PC-IgM within human omental adipose tissue and show an inverse correlation of specific IgM antibodies with MCP-1 levels and insulin resistance. Although much work remains to be done, these results provide evidence that B-1 B cells and their IgM NAbs may be important modulators of inflammation and insulin resistance in human obesity.
